These two companies are incredibly innovative biotechs, but this hasn’t translated into strong performances recently. Both stocks have significantly lagged the market over the past three years due to a combination of factors.
However, these groundbreaking companies are still looking at meaningful opportunities and catalysts that could help turn things around in the long run — and perhaps even deliver life-changing returns. Here’s why they are worth serious consideration by risk-averse investors.
This post originally appeared at The Motley Fool.